The acute lymphoblastic leukemia (ALL) is commonly called as lymphoblastic leukemia. This cancer originates from the early stage of white blood cells, known as lymphocytes, in the bone marrow. It spreads to other parts of the body, such as lymph nodes, liver, spleen, central nervous system, and other body parts. ALL is the most common type of cancer during childhood.
As per the American Cancer Society estimates, 6,590 new cases of ALL and 1,430 deaths are expected in 2016, due to ALL in the United States itself. Cancer Research UK noted 818 new cases of ALL, in 2013. The National Cancer Institute USA, states that nearly 68.1% patients survive for five years. New product launches, increasing clinical studies on ALL, and increasing access to drugs in emerging economies are propelling the growth of the market.
Acute Lymphoblastic Leukemia Therapeutics - Market Dynamics
The key factors propelling the growth of the market are -
High incidence and prevalence rate of ALL
Increasing investments in R&D
Increasing expenditure on healthcare
Advancement in pharmacology & molecular biology, to promote drug development
The factors restraining the market are -
Complications related to chemotherapy
Stringent regulatory guidelines
The market has been segmented based on chemotherapy and geography. The chemotherapy segment includes CALGB 8811 regimen, hyper - CVAD regimen, Oncaspar, linker regimen, nucleoside inhibitors, and others. Geographically the market has been segmented into North America, Europe, Asia-Pacific, the Middle East & Africa and South America.
The key players in the market are
This Report Offers:
Market definition, along with identification of key drivers and restraints for the market.
Market analysis with region-specific assessments and competition analysis on a global and regional scale.
Identification of factors instrumental in changing the market scenario, rising prospective opportunities and identification of key companies that can influence the market on a global and regional scale.
Extensively researched competitive landscape section with profiles of major companies along with their strategic initiatives and market share.
Identification and analysis of the macro and micro factors that affect the industry on both global and regional scale.
A comprehensive list of key market players, along with the analysis of their current strategic interests and key financial information.
An ideal source material for industry consultants, manufacturers and other interested and allied parties to gain critical insight into the factors driving and restraining the market, in addition to opportunities, offered.
1.1 Study Deliverables
1.2 Market Definition
1.3 General Study Assumptions
1.4 Report Descritption
2. Research Methodology
3. Executive Summary
4. Market Overview and Industry Trends
4.1 Current Market Scenario
4.2 Porter's Five Forces
4.2.1 Bargaining Power of Suppliers
4.2.2 Bargaining Power of Consumers
4.2.3 Threat of New Entrants
4.2.4 Threat of Substitute Products and Services
4.2.5 Competitive Rivalry Within the Industry
5. Market Drivers, Restraints, Opportunities and Challenges
5.1 Market Drivers
5.1.1 High Incidence and Prevalence of Acute Lymphoblastic Leukemia
5.1.2 Increasing Investments in R&D
5.1.3 Advancement in Drug Therapy Techniques
5.1.4 Advancement in Pharmacology & Molecular Biology to Promote Drug Development
5.2 Market Restraints
5.2.1 Stringent Regulations on Drugs
5.2.2 Complications Related to Chemotherapy
5.3 Market Opportunities
5.4 Market Challenges
6. Market Segmentation Chemotherapy
6.1 CALGB 8811 Regimen
6.2 Hyper - CVAD Regimen
6.4 Linker Regimen
6.5 Nucleoside Inhibitors
7. Market Segmentation by Geography
7.1 North America
7.2.3 United Kingdom
7.2.6 Rest of Europe
7.3.4 South Korea
7.3.5 Australia & New Zealand
7.3.6 Rest of Asia-Pacific
7.4 Middle East & North Africa
7.4.2 South Africa
7.4.3 Rest of MENA
7.5 South America
7.5.3 Rest of South America
8. Competitive Landscape
8.1 New Product Launches
8.2 Mergers and Acqisitions
8.3 Agreement, Collaboration and Partnerships
9. Company Profiles
9.1 Genmab A/S
9.3 Bristol Myer Squibb
9.4 Novartis AG
9.6 Celegene Corporation
9.7 Eisai Co Ltd.
10. Future Outlook of the Market